메뉴 건너뛰기

대메뉴 건너뛰기 대메뉴 바로가기

Events

go to homeHOME  >  NEWS & EVENTS  >  EVENTS
[Seminar Notification] Dr. Jeonghee Cho_11.24.2016
2016-11-21

1. Title : Cancer Genome-based EGFR-targeted therapy and clinical implication

2. Speaker : Jeonghee Cho, Ph.D.

3. Affiliation : Assistant Professor, Dankook University, Department of NanoBio Medical Science

4. Date : 11. 24. 2016 16:00-17:00

5. Place : SIMS Main Building, Auditorium 109 (1F)

6. Abstract :

Activation of the EGF receptor (EGFR) kinase, a member of the ErbB family of receptor tyrosine kinases, plays a central event in cancer pathogenesis. Somatic mutations within the kinase domain of the EGFR gene occur in lung adenocarcinoma in about 8% of patients from Europe and North America and 30% of patients from East Asia with the L858R mutation in exon 21 and exon 19 in frame-deletions accounting for 88% of these mutations. Inhibition of the activated EGFR with either tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib or anti-EGFR antibodies such as cetuximab, is an effective modality of treatment for multiple human cancers caused by oncogenic EGFR genomics alterations. In spite of the dramatic radiologic response observed with these drugs, almost all patients inevitably become resistant less than 1 year after initial treatment. In this seminar, I will talk about our findings of mechanistic insight into oncogenic activation of various cancer-driven mutant EGFR and its clinical implication of EGFR-targeted cancer therapies. In addition, I will discuss the novel therapeutic strategies for targeting oncogenic mutant EGFR to overcome the resistance to EGFR-targeted drugs based on our recent findings from integrative functional genomics and large-scale proteomics.